Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cabaletta Bio

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio to Present at the Jefferies Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Tickers CABA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.